Novartis: OmalizumabAchieved all Targets in Phase III Safety Registration

Novartis: OmalizumabAchieved all Targets in Phase III Safety Registration

An announcement made by the Swiss drugmaker Novartis AG (NVS: Quote) on Wednesday suggested about the late-breaking results omalizumab clearing all the primary and secondary endpoints of a pivotal Phase III safety registration study in chronic spontaneous urticaria or CSU.

It is a chronic and debilitating form of hives with partial approved treatment options. GLACIAL is considered as the second of three pivotal Phase III studies. These studies conduct analysis about the efficacy and safety of omalizumab in CSU.

The result derived from the study supported supported the efficacy, safety and tolerability of omalizumab in patients with refractory CSU. It is a kind of chronic and debilitating skin disease with obstinate itch and hives.

Near about 40 percent of CSU patients were unsuccessful on ntihistamines. These include those who were taking the approved dose even for the fourth time. The doses, in terms of official regulations are currently available only for treatment for CSU.

However, Omalizumab is presently not at all approved or indicated for CSU. Supervision of the submissions for omalizumab in CSU is scheduled for later times in the current year. It is a collaborated effort of Novartis and Genentech, Inc.

The data was brought forward for the first time at the European Academy of Allergy and Clinical Immunology-World Allergy Organization World Allergy and Asthma Congress 2013 in Milan which is located in Italy.


FrenchTribune Specials

Stress may be especially hard on hearts of younger women with heart disease, Res

New research suggested that stress could be mainly hard on young women’s hearts, suffering from heart disease.

Researchers gave a mentally stressful public speaking assignment to about 700 men and women suffering from heart disease and measured their blood flow to the heart.

Study leader Dr. Viola Vaccarino, chair of epidemiology...

Most Popular

Pfizer Inc. reaches closer to buy biotech Medivation Inc.

Pfizer is planning to buy biotech Medivation Inc, which...

Hyundai, Amazon team-up to enable customers to order test drives online

Bigwig automaker Hyundai and online retail giant Amazon...

Apple releases 7th developer beta and 6th public beta for macOS Sierra

Closed on the heels of the release of the seventh iOS...

UNC researchers suggest that certain facial recognition technology can be easily

Researchers in the security and computer vision fields...

Poll

Can Greece Come out of Economic Problems: